IMV's pipeline reflects our focus on Immuno-Oncology and other serious diseases. Our lead candidate, DPX-Survivac is being evaluated in three ongoing Phase 2 studies alone or in combination with Merck's Keytruda.
On June 25, 2020, Directors of the Company will present the annual report containing information for shareholders about IMV's performance and strategy. This year’s annual meeting will be held virtually.
In response to the pandemic, IMV works on a vaccine to protect against COVID-19. We believe our targeted approach has the potential to optimize and exceed the safety and efficacy profile of conventional vaccines.
IMV Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform (DPX). This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as in combination therapy in multiple clinical studies with Merck’s Keytruda®. IMV is also developing a DPX-based vaccine to fight against COVID-19.
The method and manner in which directives are delivered to our immune systems, and their initial responses, are critical components of leveraging the disease-fighting potential of human immunity. At IMV, we believe that we have found a groundbreaking way to deliver the messages to command and sustain that pivotal response. By using our unique delivery platform, we believe we have the capacity to mobilize our immune system in a manner that will open a new era in immunotherapies and disease prevention.
Driven by the fundamental science underscoring our platform, our R&D teams leverage the unique mechanism of action of our 100% oil-based delivery formulations, coupled with proprietary targets, to harness human immunity in a truly novel way.
Our lead candidate is priming tumors for today’s strongest anti-cancer agents. We are focused on developing combination therapies that can improve treatment outcomes for some of today’s toughest cancers. Read about our clinical trials here.
Disrupting Disease. Transforming the Power of Human Immunity. We are committed to building value for our partners and our investors, while working to help fill the significant gaps in today’s treatment landscape.
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV